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0735-6757/© 2016 The Authors. Published by Elsevier IncThe direct oral anticoagulants (DOACs) provide a number of clinical advantages over vitamin K antagonists for
the treatment of thromboembolism, including improved efﬁcacy and safety, as well as no need for regular mon-
itoring of anticoagulant effect. However, as with all anticoagulants, bleeding complications may occur, and anti-
coagulant reversal may be required in speciﬁc clinical situations, such as in patients experiencing spontaneous or
traumatic bleeds, or in anticoagulated patients requiring emergency surgery or other invasive procedures. There-
fore, several reversal agents for the DOACs are in development. This includes the speciﬁc reversal agent
idarucizumab, which has been approved by the U.S. Food and Drug Administration and the EuropeanMedicines
Agency for use in patients treated with dabigatran when urgent reversal of its anticoagulant effects is needed.
Idarucizumab is a humanized monoclonal antibody fragment that binds with high afﬁnity to free and
thrombin-bound dabigatran, resulting in an almost irreversibly bound idarucizumab-dabigatran complex and
thereby neutralizing dabigatran’s anticoagulant activity. The reversal of the anticoagulant effects of dabigatran
by idarucizumab has been demonstrated in animal bleeding models, in healthy volunteers with a range of ages
and renal function, and in anticoagulated patients. In the phase 1 trials, at doses of 2 g or greater, idarucizumab
resulted in immediate and complete reversal of the dabigatran anticoagulant effects and was well tolerated. In
the absence of dabigatran, idarucizumab showed no effect on coagulation parameters or thrombin formation.
These ﬁndings provide initial evidence that idarucizumab could provide a safe and effective means of reversing
anticoagulant activity in patients treatedwith dabigatran inneed of emergency surgery or in emergency bleeding
situations.
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. This is an open access article underDirect oral anticoagulants (DOACs), such as the direct factor (F) Xa in-
hibitors rivaroxaban, apixaban, and edoxaban, and the direct thrombin
inhibitor dabigatran etexilate, are alternatives to vitamin K antagonists
(VKAs) for the treatment of and reduction of risk from thromboembolic
disease [1-4]. The DOACs have a number of clinical advantages over
VKAs, including a lower risk of intracranial hemorrhage and a possible
reduction in major bleedingassociated mortality in patients with
nonvalvular atrial ﬁbrillation and in patients receiving acute treatment
for venous thromboembolism [5-7]. However, as with all anticoagulants,
bleeding complications are still a concern, and there is a need for antico-
agulant reversal in speciﬁc clinical situations, such as in patients
experiencing spontaneous or traumatic bleeds or in those requiring
emergency surgery or other invasive procedures. As a result, DOAC-
speciﬁc reversal agents have been developed for clinical situations, in
which, urgent anticoagulation reversal is required. These agents include
idarucizumab (Boehringer Ingelheim, Ridgeﬁeld, Conn), andexanet alfathe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Calif), and ciraparantag (aripazine, PER-977; Perosphere, Danbury,
Conn). Idarucizumab is a monoclonal antibody fragment that binds to
the direct thrombin inhibitor dabigatran, thereby immediately reversing
its anticoagulant effects [8]. Andexanet alfa is an FXa decoy molecule
with no intrinsic coagulation activity that has been designed to bind
both direct FXa inhibitors and indirect FXa inhibitors (eg, fondaparinux
and enoxaparin) [9,10]. Ciraparantag is a potential antidote for direct
and indirect FXa inhibitors and direct thrombin inhibitors, as well as
unfractionated heparin and low-molecular-weight heparins, such as
enoxaparin [11].
This review will focus on idarucizumab, which received accelerated
approval by the U.S. Food and Drug Administration in October 2015 and
the European Medicines Agency in November 2015 for use in patients
treated with dabigatran when reversal of the anticoagulant effects of
dabigatran is needed (ie, for emergency surgery/urgent procedures or
if there is life-threatening or uncontrolled bleeding) [12,13].
1. Biochemical composition and mode of action
Idarucizumab was identiﬁed by screening dabigatranspeciﬁc mono-
clonal antibodies generated by immunizing mice with dabigatran-
derived haptens coupled to carrier proteins. Monoclonal antibody frag-
ments that were produced in Chinese hamster ovary cells were selected
according to potency of dabigatran-binding afﬁnity. These were then
humanized to minimize immunogenicity [8].
With respect to themolecular recognition and binding of dabigatran,
idarucizumab has structural similarities to thrombin, but idarucizumab
lacks enzymatic activity (Fig. 1; please also see mode of action video in
supplemental materials) [8,14]. Idarucizumab’s binding to dabigatran
is mediated by hydrophobic interactions, Hbonds, and a salt bridge,
which result in a high afﬁnity for dabigatran (dissociation constant
[KD] 2.1 ± 0.6 pM, approximately 350-fold stronger than dabigatran’s
afﬁnity for thrombin) [8]. This high afﬁnity corresponds with a rapid
on rate and very slow off rate, resulting in an almost irreversible binding
of idarucizumab to dabigatran [8,15]. Despite the structural similarities
with thrombin, idarucizumab does not bind to thrombin substrates, in-
cluding FV, FVIII, FXIII, or ﬁbrinogen. Furthermore, idarucizumab does
not exhibit thrombin-like activity, as demonstrated by a lack of activity
in coagulation or platelet aggregation tests [8]. Idarucizumab added to
plasma in vitro did not alter clotting in the diluted thrombin timeThrombin
MW ~ 37 kDaltons
Dabigatran
MW 472
Fig. 1. Structure and relative sizes of thrombin (FIIa), dabigatran, and(dTT) assay, nor shorten the clotting time of prothrombin-depleted
plasma. Idarucizumab did not convert the main substrate of thrombin,
ﬁbrinogen, into ﬁbrin, as measured by ﬁbrinopeptide A (FPA), nor in-
crease thrombin generation when added to plasma, as demonstrated
by thrombin generation assays. In in vitro platelet aggregation studies,
idarucizumab did not induce platelet aggregation alone or affect
protease-activated receptor 1–induced platelet aggregation by the
thrombin receptor-activating peptide SFLLRN [8].
2. Preclinical assessment of idarucizumab’s reversal of dabigatran’s
anticoagulant activity
The reversal effects of intravenous idarucizumabwere investigated in
rats treatedwith dabigatranwhen bothwere given in equimolar concen-
tration [8]. Dabigatran alone prolonged thrombin time (TT) by 4-fold and
activated partial thromboplastin time (aPTT) by 2-fold, over controls.
This anticoagulant activity was completely reversed by idarucizumab
within 1 minute of administration.
The ability of idarucizumab to reverse dabigatran’s anticoagulant ef-
fects was compared with the effects of nonspeciﬁc procoagulant strate-
gies by using in vitro studies of platelet and coagulation responses to
vessel injury under ﬂow conditions [16]. Dabigatran added in vitro to
human blood from healthy donors reduced ﬁbrin coverage by 85% and
platelet deposition by 35%. Dabigatran also altered the dynamics of
thrombin generation, prolonging the lag-phase and reducing themaximal
thrombin peak and thrombin generation, as well as prolonging clotting
time (CT) and clot formation time (CFT). These effects were completely
reversedwith the addition of idarucizumab (0.3, 1, and 3mg/mL). In con-
trast, prothrombin complex concentrates (PCCs; 70 IU/kg) and activated
PCCs (aPCCs; 25 and 75 IU/kg) only partially reversed dabigatran-
associated changes in ﬁbrin deposition, CT, and CFT, as well as increasing
thrombin generation levels beyond those of predabigatran levels.
The reversal effects of idarucizumab (30 and 60 mg/kg) were com-
pared with PCC (30 and 60 IU/kg), aPCC (30 and 60 IU/kg), and recom-
binant FVIIa (90 and 180 μg/kg) ex vivo in a blunt liver trauma porcine
model [17]. Dabigatran etexilate (oral 30 mg twice daily for 3 days;
followed by intravenous infusion of 0.77 mg/kg/h for 30 minutes and
0.52 mg/kg/h for 60 minutes) was administered to the animals before
injury to achieve consistent supratherapeutic plasma concentrations
as demonstrated by prolonged prothrombin time (PT), aPTT, CT, and
CFT. When idarucizumab was added to ex vivo blood samples, theIdarucizumab
MW ~ 48 kDaltons
idarucizumab. Reprinted with permission from Pollack et al. [14].
Fig. 3. (A) Effect of increasing doses of prothrombin complex concentrate (PCC) on
reducing dabigatran-associated bleeding. (B) Thrombin-antithrombin complex (TAT)
was also measured over time. Data shown as mean ± SD, n = 8 per group; *P b .05.
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ration of PT, aPTT, CT, and CFT to baseline levels. Prothrombin complex
concentrates and aPCC reduced the anticoagulant effects of dabigatran
but to a lesser extent than idarucizumab, as demonstrated by signiﬁcant
decreases in PT, CT, and CFT, with no effect on aPTT. Recombinant FVIIa
had no effect on any of the coagulation parameters. Idarucizumab, un-
like PCC and aPCC, also reduced themean plasma concentrations of un-
bound dabigatran (measured by dTT) to below the limit of quantitation.
In vivo administration of idarucizumab also reduced dabigatran-
associated bleeding and mortality in a porcine trauma model [18].
Animals were treated with supratherapeutic doses of dabigatran
(dosed as described above) before treatment with idarucizumab (30,
60, or 120 mg/kg), and blood loss and hemodynamic variables were
monitored for up to 4 hours after injury. Anticoagulation with
dabigatran resulted in signiﬁcantly higher blood loss than in
nonanticoagulated animals and a 100% mortality (Fig. 2) [18].
Idarucizumab immediately reversed the anticoagulant effects of
dabigatran and was associated with a signiﬁcant reduction in blood
loss when administered 15 minutes after trauma; bleeding stopped
within 15 minutes of treatment. In a dose-dependent fashion, the low-
est dose (30 mg/kg) reduced blood loss by 47% and resulted in an 83%
reduction in mortality, and all animals that received 60 or 120 mg/kg
idarucizumab survived, with total blood loss being reduced by 64%
and 62%, respectively. All coagulation tests were also restored to base-
line in a dose-dependent manner, with the highest dose of
idarucizumab (120 mg/kg) restoring coagulation for the duration of
the study, and thrombin generation normalized dose-dependently
after idarucizumab administration.
Four-factor PCC (50 or 100 IU/kg) and aPCC (50 IU/kg) have also been
shown to be effective in reducing dabigatranassociated blood loss and
improving coagulation in a polytrauma porcine model, although the co-
agulation tests, such as aPTT, dTT, and ecarin clotting time (ECT), poorly
reﬂected the effects of either PCC or aPCC treatment on dabigatran
anticoagulation [19,20]. The reduction of dabigatranassociated blood
loss with PCC was dose-dependent and signiﬁcantly reduced with 50
and 100 IU/kg, whereas 25 IU/kg had no effect on blood loss (Fig. 3).
There was also an elevated state of coagulation and hyperﬁbrinolysis
with increasing doses of PCC, measured as increased thrombin genera-
tion, thrombineantithrombin complex, and D-dimer levels [19]. The
lower dose of both PCC and aPCC (25 IU/kg) did not produce sustained
procoagulant effects and also did not reduce blood loss [19,20]. Thus,
this suggests sufﬁcient thrombin generation to overcome the dabigatran
anticoagulant effect is required to control bleeding; however, excessive
thrombin generation can further shift the balance to a procoagulant
state.Fig. 2. Effects of posttrauma idarucizumab on blood loss in animals treated with
dabigatran. Reprinted with permission from Elsevier from Grottke et al. [18] The dashed
vertical line (t = 0) indicates time of liver injury, and the dotted vertical line indicates
the time of intervention (t = 15 minutes). Data are shown as mean ± SD, n = 6 per
group; *P b .05 versus all groups. IDA = idarucizumab.3. Early clinical evidence for idarucizumab
Idarucizumab has been evaluated in healthy male volunteers in a
phase 1 randomized, placebo-controlled study (NCT0168830), which
comprised 2 parts: a single risingdose evaluation of the safety, tolerabil-
ity, and pharmacokinetics of idarucizumab alone (part 1) and a dose-
ﬁnding, proof-of-concept assessment of idarucizumab in subjects
pretreated with dabigatran etexilate (part 2) [15,21]. The pharmacoki-
netics and reversal effects of idarucizumab have also been evaluated
inmiddle-aged and elderly individuals and thosewithmild ormoderate
renal impairment in a separate randomized, double-blind, 2-way cross-
over phase 1b study [22].3.1. Pharmacokinetics
In part 1 of the ﬁrst phase 1 trial, 110 male healthy volunteers (aged
18-45 years) received single doses of intravenous idarucizumab (1-hour
infusion: 20 mg to 8 g; 5-minute infusion: 1 g, 2 g, and 4 g) or placebo
[21]. Peak plasma concentrations were achieved at or shortly after the
end of the 1-hour or 5-minute infusions. Both geometric mean peak ex-
posure (Cmax) and total exposure (AUC0-∞) increased with increasing
dose (Fig. 4). The geometric mean initial half-life across doses was 39-
54 minutes, and the geometric mean terminal half-life for doses
≥600 mg was 4.5-8.1 hours. After infusion, geometric mean
idarucizumab plasma concentrations rapidly declined, reaching ≤4% of
peak concentrations at 4 hours. This corresponded with the observed
idarucizumab renal excretion predominantly occurring in the ﬁrst
4-hour collection period. Together with a limited distribution (approxi-
mating blood volume), this suggests that the decline in plasma concen-
trations of idarucizumab was predominantly due to renal elimination.
The fact that the majority of the idarucizumab renal excretion occurred
in the ﬁrst 4 hours after infusion may account for a transient increase
in urinary protein, which occurred in a dose-related manner after
doses of ≥1 g (discussed further in the “Safety” section below). Trace
Fig. 4.Geometricmean idarucizumab plasma concentration-time proﬁles from the start of
a single infusion of 1 g to 4 g idarucizumab for 5 minutes on (A) a linear scale and (B) a
semi-log scale. Reprinted with permission from Glund et al. [21].
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after the 1-g infusion and up to 24 hours after higher doses.
3.2. Reversal of dabigatran anticoagulant activity
Part 2 of the above study assessed the reversal of the anticoagulant
effects of dabigatran by idarucizumab (single 5-minute infusion of 1 g,
2 g, or 4 g, or 2 × 5-minute infusions of 5 g + 2.5 g 1 hour apart). Indi-
viduals were pretreated to dabigatran steady-state with dabigatran
etexilate 220 mg twice daily for 3 days, followed by a ﬁnal dose on
day 4 [15], a dosing regimen that resulted inmean peak dabigatran con-
centrations in the healthy volunteers thatwere similar to corresponding
levels in patients in the Randomized Evaluation of Long-term
anticoagulation therapY (RE-LY) study who received dabigatran
150 mg twice daily [23].
All doses of idarucizumab resulted in immediate and complete re-
versal of dabigatran anticoagulant activity, as indicated by a normaliza-
tion of coagulation times directly after the end of infusion, including
coagulation measurements of dTT, ECT, aPTT, and TT [15]. For doses
≥2 g this effect was sustained over the entire observation period of 72
hours (Fig. 5), although small increases in the highly sensitive TT
above the upper limit of normal were observed with the 2-g (2 hours
after dose) and 4-g (12-24 hours after dose) idarucizumab doses (but
not 5 g + 2.5 g). Thismaybe explained by the narrow normal range for
TT resulting from low variability of baseline TT clotting times in these
healthy individuals, as well as the high sensitivity of TT for dabigatran.
The reversal effect of idarucizumabwas quantiﬁed by calculating the
ratio of theday-4 area under thedabigatran effect curve over 2-12hours
after dabigatran administration (AUEC2-12) to the day-3 AUEC2-12. For
dTT, idarucizumab (1 g, 2 g, 4 g, and 5 g + 2.5 g) reduced this ratio by
74%, 94%, 98%, and 99%, respectively. The dTT and ECT seemed to be
the most suitable assays for assessing the anticoagulant activity of
dabigatran and its reversal by idarucizumab, on the basis of the low var-
iability of baseline clotting times and close correlation with unbound
dabigatran concentration (ie, dabigatran not bound to idarucizumab
or plasma proteins; R2 = 0.86 and R2 = 0.89, respectively). Unbounddabigatran was determined by ultraﬁltration of plasma followed by
high-performance liquid chromatography tandem mass spectrometry,
and can be considered a rough measure of pharmacologically active
dabigatran.
Increases in total dabigatran plasma concentrations (ie, bound and
unbound dabigatran, including active metabolites) were observed im-
mediately after idarucizumab dosing, which can be attributed to the pe-
ripheral distribution of dabigatran and idarucizumab’s mode of action
(ie, speciﬁc binding and neutralization of dabigatran). The increase in
total dabigatran plasma concentrations then results from the redistribu-
tion of unbound dabigatran from the periphery to the central compart-
ment. Because idarucizumab has a small volume of distribution at
steady state (Vss, 8.9 L) it ismostly conﬁned to the plasma compartment
[12]. In contrast, dabigatran has a larger volume of distribution (Vss, 50-
70 L) [1] and is, therefore, distributed between the plasma compart-
ment and the periphery, in a dynamic equilibrium. After idarucizumab
infusion, dabigatran in the plasma compartment is promptly neutral-
ized via idarucizumab binding, resulting in a decrease in unbound
dabigatran plasma concentration. Dabigatran then redistributes from
the periphery to the plasma compartment to maintain the equilibrium,
as long as free idarucizumab is present.
Directly after idarucizumab infusion in this study, geometric mean
concentrations of unbound dabigatran were at or close to lower limit
of quantiﬁcation (LLOQ; 1 ng/mL) and remained b10 ng/mL after the
2-g dose and b5 ng/mL after the 4-g and 5-g + 2.5-g doses over 72
hours (Fig. 6) [15]. Active dabigatran plasma concentrations (as mea-
sured by the calibrated dTT assay, HEMOCLOT; HYPHEN BioMed,
Neuville-sur-Oise, France) also decreased to and remained b50 ng/mL
(LLOQ) over 72 hours after the 2-g, 4-g, and 5-g + 2.5-g doses of
idarucizumab.
Although this study did not measure the effect of idarucizumab on
bleeding, a potential bleeding marker was evaluated. Measurement of
FPA levels at awound site represents an indirectmeasure of local activa-
tion of coagulation, because FPA is released upon ﬁbrinogen conversion
to ﬁbrin, and thus, levels are raised at wound sites. Therefore, the effect
of idarucizumab on restoring ﬁbrin generation at a nonpenetrating
wound site in individuals pretreated with dabigatran was evaluated
by measuring FPA levels in blood shed from the incision site. After 3
days of dabigatran treatment, levels of FPA decreased by 87% (2.5
hours after dose) and 73% (6 hours after dose). Increasing doses of
idarucizumab resulted in dose-dependent increases in ﬁbrin formation,
returning FPA to 24% to 95% of predabigatran levels 30 minutes after
idarucizumab administration.
3.3. Effect of renal function on the pharmacokinetics/pharmacodynamics of
idarucizumab
The pharmacokinetics and reversal effects of idarucizumab in
middle-aged and elderly individuals were compared with those in
individuals with mild or moderate renal impairment (creatinine clear-
ance: 60 to b90 [n = 12] or 30 to b60 mL/min [n = 6], respectively)
in a separate randomized, doubleblind, 2-way cross-over phase 1b
study (N = 46) [12,22]. Participants were pretreated with dabigatran
etexilate (healthy volunteers: 220 mg twice daily; renally impaired:
150 mg twice daily) and then received a 5-minute intravenous infusion
of idarucizumab (1 g, 2.5 g, 5 g, or 2 × 2.5 g).
Compared with healthy individuals, the total clearance was reduced
in individuals with renal impairment, which resulted in an increase in
idarucizumab’s area under the curve by 43.5% and 83.5% in those with
mild and moderate renal impairment, respectively.
Renal impairment and old age, however, were not found to impact
the reversal effect of idarucizumab [22]. In healthy and elderly volun-
teers and those with renal impairment, idarucizumab completely re-
versed dabigatran anticoagulant activity by the end of the 5-minute
infusion, as demonstrated by unbound dabigatran levels near the
LLOQ and a return of prolonged clotting times to baseline levels,
Fig. 5. Effect of idarucizumab or placebo infusion on coagulation variables, (A) dTT, (B) ECT, (C) aPTT and (D) TT, by dose group Reprintedwith permission from Elsevier from Glund et al.
[15] Dotted horizontal lines show upper limit of normal. “0 h” and the arrows on x axes show when the idarucizumab or placebo infusion ended. Solid horizontal lines show the mean
baseline measurement. Data points show mean; error bars show standard error. aPTT = activated partial thromboplastin time; DE = dabigatran etexilate; dTT = diluted thrombin
time; ECT = ecarin clotting time.
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idarucizumab 2 months after the ﬁrst infusion in healthy volunteers
also completely reversed dabigatran-induced anticoagulation, and 24
hours after idarucizumab, dabigatran etexilate could be administered
to re-establish anticoagulation [24].
3.4. Lack of Antithrombotic or prothrombotic properties
In the ﬁrst phase 1 study, idarucizumab (8 g infused over 1 hour or
4 g infused over 5 minutes) administered alone had no effect on coagu-
lation parameters (dTT, ECT, TT, aPTT, and activated clotting time)mea-
sured 15minutes after the end of the infusion (ie, at peak plasma levels)
[21]. Furthermore, these doses of idarucizumab did not affect endoge-
nous thrombin formation [21]. Similarly, in part 2 of this trial when
idarucizumab (at doses ≥2 g) fully inhibited dabigatran anticoagulant
activity, thrombin generation variables were restored to pre-
dabigatran levels but did not exceed these baseline values [15]. These
ﬁndings conﬁrm the in vitro data indicating the lack of any antithrom-
botic or prothrombotic properties of idarucizumab [8].3.5. Safety
Idarucizumab was well tolerated in each of the phase 1 trials
described above, with no relationships observed between idarucizumab
dose and adverse event frequency. There were no severe or serious
adverse events, no dose-related events, and no discontinuations due
to adverse events [15,21,22]. In the ﬁrst phase 1 study, no clinically
relevant differences were reported regarding the overall incidence
of adverse events between the placebo and idarucizumab groups
[21]. Five individuals (placebo, n=2; idarucizumab, n=3)were reported
to have adverse events that were considered to be drug-related by
the investigator. With the exception of 1 case of migraine of moderate
intensity, which occurred in an individual who received idarucizumab
8 g, all drugrelated adverse effects weremild. In the idarucizumabtreated
individuals, they comprised headache (n = 2), erythema (n = 1), and
migraine (n = 1), and in the placebo group, pain in extremity (n = 1)
and upper abdominal and chest pain (n = 1). Local infusion-site
reactions (mild erythema, swelling, redness, and pain) were limited
to those in the 1-hour infusion group. No clinically relevant ﬁndings
Fig. 6. Plasma concentration of unbound dabigatran after infusion of placebo or
idarucizumab. Reprinted with permission from Elsevier from Glund et al. [15]
Dabigatran etexilate was administered at −2 hours (arrows) on the x axis on days 3
and 4. Placebo or idarucizumab infusion ended at 0 h (arrow) on the x axis on day 4
(end of ﬁrst infusion for the 5-g + 2.5-g group). Data points show geometric mean
values. DE = dabigatran etexilate.
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cardiac telemetry, and physical examination. A transient, dose-
dependent increase in low molecular weight protein excretion in urine
was observed in individuals receiving idarucizumab. This effect was con-
sidered to be secondary to saturation of the renal tubular uptake process
for small proteins, and there were no corresponding changes suggesting
acute tubular injury or loss of function. All values of urinary protein excre-
tion normalized within 4-12 hours after the infusion.
Similarly, in part 2 of this trial, no unexpected or clinically relevant
safety concerns for idarucizumab were observed [15]. Adverse events
considered to be drug related were infusion site erythema and hot
ﬂushes in a subject who received dabigatran plus idarucizumab 1 g, ep-
istaxis in a subjectwho received dabigatran plus idarucizumab5 g+2.5 g,
and infusion site hematoma in a subject receiving dabigatran plus placebo.
All these adverse events were of mild intensity.
3.6. Immunogenicity
There is a potential for immunogenicity with idarucizumab as with
all proteins. Immunogenicity was therefore evaluated using an
electro-chemiluminescence-based assay and plasma samples from 283
individuals, of whom 224 were treated with idarucizumab [12,25].
Pre-existing antibodies (ie, those detected in baseline samples) with
cross-reactivity to idarucizumabwere detected in 33 of the 283 individ-
uals (12%) [25].Most of these pre-existing antibodies had low titers, and
there was no impact on the pharmacokinetics or the reversal effect of
idarucizumab or hypersensitivity reactions in individuals with pre-
existing antibodies. Nine individuals treated with idarucizumab (4%)
had a low titer, treatment-emergent, possibly persistent anti-
idarucizumab antibody response.
The epitope speciﬁcity of antibodies to idarucizumab was deter-
mined with probe molecules. None of the pre-existing antibodies
interactedwith the dabigatran-binding region of idarucizumab. Similar-
ly, themajority of the treatment emergent antibodies had speciﬁcity for
the C-terminus, which is not a region that dabigatran binds to. Of the re-
maining treatment-emergent antibodies, 2 of 19 (10%) had speciﬁcity
for the idarucizumab variable region, 2 (10%) had mixed speciﬁcity,
and 1 (5%) had undetermined speciﬁcity [25].3.7. Dose selection
Selection of the idarucizumab dose for clinical use was based on the
goal of neutralizing the total body load of dabigatran in patients with
atrial ﬁbrillation. The binding stoichiometry between idarucizumab
and dabigatran is 1:1, that is, 1 molecule of idarucizumab binds 1 mole-
cule of dabigatran. Total body load of dabigatran can be estimated from
the plasma concentrations and the apparent volume of distribution. On
the basis of the average peak concentrations of dabigatran observed in
patients with atrial ﬁbrillation who received dabigatran 150 mg twice
daily in the RE-LY study (which enrolled a cohort of patients aged ≥65
years with a moderate-to-high comorbidity burden), it was calculated
that a dose of 2 g of idarucizumab would completely bind the total
body load of dabigatran in patients at the 70th percentile of dabigatran
concentrations (ie, this dose would result in full reversal of dabigatran
effects in 70% of patients) [21,23,26]. However, higher doses of
idarucizumab may be required to achieve full reversal in some patients
because the peak dabigatran concentrations in the RE-LY study varied
by more than 5-fold [21,23]. Additionally, patients with bleeding and
those with renal impairment may have higher dabigatran concentra-
tions than those without bleeding or renal impairment. Therefore, 5 g
was chosen as a dose that was estimated to reverse the 99th percentile
of concentrations observed in the RE-LY study in patients with moder-
ate renal dysfunction [27,28]. Such a dose should cover the vastmajority
of patients in clinical practice. In the phase 1 study involving male and
female individuals of different ages and renal function, administration
of 5-g or 2 × 2.5-g doses of idarucizumab resulted in sustained reversal
of dabigatran-induced anticoagulation [22]. Therefore a total dose of 5 g
idarucizumab has been selected as the dose for further clinical testing.
4. Conclusions
Idarucizumab, a humanized anti-dabigatran Fab, binds dabigatran
with a fast on and slow off rate, resulting in almost irreversible binding,
with a binding afﬁnity 350-fold higher than dabigatran’s afﬁnity for
thrombin. As a result, idarucizumab binds free and thrombin-bound
dabigatran, neutralizing its anticoagulant activity. In animal bleeding
models, idarucizumab reversed the anticoagulant effects of dabigatran
and stopped the bleeding. Immediate and complete reversal of the anti-
coagulant effects of dabigatran by idarucizumab has also been demon-
strated in healthy young volunteers with normal renal function,
elderly volunteers aged 65-80 years, and in volunteers aged 45-80
years with mild or moderate renal impairment. After intravenous infu-
sion in volunteers, idarucizumab concentrations peak within minutes,
followed by rapid elimination. In the absence of dabigatran,
idarucizumab has no effect on coagulation parameters or thrombin for-
mation. Itwaswell tolerated at all administered doses in the phase 1 tri-
als. These preclinical and early clinical data suggest that idarucizumab
may provide a safe and effectivemeans of reversing anticoagulant activ-
ity in emergency situations in patients treated with dabigatran.
Appendix A. Supplementary data
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ajem.2016.09.050.
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